GlassScriptPhysician profile
Silverio D Alvarez
NPI 1740758416
$5,500.13
in general payments reported to CMS, 2019-2025
22 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,543 · 2022: $1,194 · 2023: $839 · 2024: $731 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,763.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,460.91 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,315.19 | 2021-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $578.60 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Daiichi Sankyo INC. | $474.48 | 2021-2022 | |
| Lilly USA, LLC | $314.74 | 2021-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $276.26 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $248.54 | 2021 | |
| Janssen Pharmaceuticals, INC | $192.11 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.55 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $84.24 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Amarin Pharma, INC. | $70.45 | 2021 | |
| Boston Scientific Corporation | $69.13 | 2021-2024 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $53.57 | 2021 | |
| Abbvie INC. | $46.53 | 2021-2022 | |
| Shield Therapeutics INC | $40.24 | 2024-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $22.26 | 2024 | |
| Neurocrine Biosciences, INC. | $21.65 | 2024 | Ingrezza |
| Biohaven Pharmaceutical Holding Company LTD. | $19.92 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.28 | 2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $17.86 | 2025 | Voquezna |
| Medtronic, INC. | $17.62 | 2024 | Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silverio Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.